First of all, let's note that healthcare and biotech stocks have been a subject to a broad selloff, some more than others. The SPDR S&P Biotech ETF (XBI) has declined more than the major indexes.
The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock. Among the near-term catalysts that can boost the stock value, analysts note great strategic partnerships and a strong pipeline. Many traders are betting that Sorrento Therapeutics will become a key player in the immuno-oncology (I/O) space.
The bears are skeptical about the convertible debt that the company incurred, as well as less attractive financing deals. J Capital Research asserts that the financing deals have benefited a select group of investors who are close to the CEO.
www.finstead.com/bit...ction-august-20-2018
The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock. Among the near-term catalysts that can boost the stock value, analysts note great strategic partnerships and a strong pipeline. Many traders are betting that Sorrento Therapeutics will become a key player in the immuno-oncology (I/O) space.
The bears are skeptical about the convertible debt that the company incurred, as well as less attractive financing deals. J Capital Research asserts that the financing deals have benefited a select group of investors who are close to the CEO.
www.finstead.com/bit...ction-august-20-2018